Table 4 Comparative analysis of the study population based on severity (ANOVA, p< 0.0001 for all variables)
From: Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
Variable | Mild/moderate patients (N = 6484) | Severe patients (N = 25,849) | Critical patients (N = 13,027) |
|---|---|---|---|
ALT (mean, standard deviation) | 49.98, 53.77 | 57.12, 67.01 | 81.67, 99.55 |
AST (mean, standard deviation) | 49.76, 51.32 | 59.69, 62.58 | 96.65, 106.8 |
AlkP (mean, standard deviation) | 92.9, 45.88 | 97.45, 50.19 | 116.3, 64.19 |
Total bilirubin (mean, standard deviation) | 0.6235, 0.414 | 0.7002, 0.4667 | 0.9219, 0.6702 |
Albumin (mean, standard deviation) | 3.15, 0.69 | 2.94, 0.66 | 2.41, 0.66 |
PT (mean, standard deviation) | 12.94, 3.99 | 13.45, 4.78 | 14.54, 6.06 |
Lipase (mean, standard deviation) | 145.07, 165.63 | 183.45, 254.55 | 217.47, 329.47 |
LDH (mean, standard deviation) | 353.57, 201.65 | 365.77, 196.79 | 529.81, 286.05 |
Mortality (N) | 309 (4.77%) | 1720 (6.65%) | 4575 (35.12%) |
Length of stay (days) | 2.84, 4.45 | 6.76, 6.64 | 13.68, 11.71 |